Understanding Internal Release Limits

Mary Ann Gorko

Mary Ann Gorko is principal statistician at AstraZeneca.

,
Gregory Larner

Gregory Larner is a statistics manager with Pfizer Scientific and Laboratory Services in Kalamazoo, Michigan.

,
Niels Væver Hartvig

Niels Væver Hartvig, PhD, is a principal specialist, at Novo Nordisk A/S, Smørmosevej.

,
Stan Altan

Stan Altan is senior director at Janssen Pharmaceutical R&D.

,
Mark Johnson

Mark Johnson is senior principal statistician at AbbVie’s research department.

,
Yilje Dong

Yilje Dong is an independent consultant at Novo Nordisk A/S.

,
Stacy Sherling

Stacy Sherling is research scientist at Eli Lilly.

Pharmaceutical Technology, Pharmaceutical Technology-10-02-2018, Volume 42, Issue 10
Pages: 30–39

Internal release limits help ensure that a batch of drug product remains within specifications throughout its shelf life. This article explores what internal release limits are and why they are important.

The manufacture of pharmaceutical and biopharmaceutical drug products is a complex process that takes place in a highly regulated environment (1). Success requires a combination of scientific, engineering, and regulatory knowledge. One critical part of drug development is formulating the compound into a final drug product, ensuring that desirable physical and chemical properties remain stable for an acceptable period of time and meet regulatory and commercial requirements for specifications for the product (2).

One key requirement is that the drug retain its physical and chemical properties such as potency, purity, and bioavailability for a set period of time, referred to as its shelf life (3). Once a shelf life has been defined for the drug, control strategies must be instituted to provide a high level of assurance that batches of drug product released into the market remain within specifications throughout the drug’s shelf life.

One critical control strategy is the use of internal release limits. This article discusses how these limits are calculated and applied to ensure drug product quality. Click

to view a PDF of this article.

Peer-Reviewed

Submitted: May 29, 2018 
Accepted: June 19, 2018

About the Authors

Mary Ann Gorko* is technical manager of statistics at AstraZeneca, maryann.gorko@astrazeneca.com; Stan Altanis senior director at Janssen Pharmaceutical R&D; Yilje Dong is an independent consultant; Niels Vaever Hartvig is principal big data analyst at Novo Nordisk A/S; Mark Johnson is senior principal statistician at AbbVie’s research department; Gregory Larner is manager of statistics at Pfizer; and Stacy Sherling is research scientist at Eli Lilly.

*To whom all correspondence should be addressed.

Article Details

Pharmaceutical Technology
Vol. 42, No. 10
October 2018
Pages: 30, 32, 34, 36, 38–39

Citation

When referring to this article, please cite it as S. Altan, Y. Dong, M.A. Gorko, N. V. Hartvig, M. Johnson, G. Larner, and S. Sherling, "Understanding Internal Release Limits," Pharmaceutical Technology 42 (10) 2018.

download issueDownload Issue : Pharmaceutical Technology-10-02-2018